Journal
JOURNAL OF CLINICAL MEDICINE
Volume 11, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/jcm11072003
Keywords
TAVR; nonagenarians; embolic protection; stroke; interventional devices; percutaneous valve therapy
Categories
Funding
- Open Access Publication Fund of the University of Duisburg-Essen
Ask authors/readers for more resources
This study evaluated the safety and efficacy of cerebral embolic protection devices (CEPDs) during transcatheter aortic valve replacement (TAVR) in nonagenarian patients. The results showed that the use of CEPDs did not increase access site complications and was feasible and safe in nonagenarian TAVR patients. Age alone is no longer a contraindication for TAVR.
Background: Transcatheter aortic valve replacement (TAVR) improves the survival and life quality of nonagenarian patients with aortic stenosis. Stroke remains one of the most worrisome complications following TAVR. Cerebral embolic protection devices (CEPDs) may reduce neurological complications after TAVR. This study evaluated the safety and efficacy of CEPDs during TAVR in nonagenarian patients. Methods: Between January 2018 and October 2021, 869 patients underwent transfemoral TAVR (TF-TAVR) at our center. Of these, 51 (5.9%) patients were older than ninety years. In 33 consecutive nonagenarian patients, TF-TAVR was implanted without CEPDs using balloon-expandable valves (BEVs) and self-expandable valves (SEVs). Eighteen consecutive nonagenarians underwent TF-TAVR using a CEPD (CP group). Follow up period was in-hospital or 30 days after the procedure, respectively. Results: Minor access site complications occurred in two patients (3.9%) and were not CEPD-associated. Postinterventional delirium occurred in nine patients (17.6%). Periprocedural minor non-disabling stroke and delirium occurred in ten patients (19.6%). Periprocedural major fatal stroke occurred in two patients in the BEV group (3.9%). Two patients in the BEV group died due to postinterventional pneumonia with sepsis. The mortality rate was 7.8%. The results did not differ between the groups. Conclusions: Age alone is no longer a contraindication for TAVR. CEPD using the Triguard 3 system in nonagenarian TAVR patients was feasible and safe and did not increase access site complications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available